Evolution of the Average Target: Exagen Inc.

Evolution of the Average Target - Exagen Inc.

Evolution of the Target Price: Exagen Inc.

Evolution of the Target Price - Exagen Inc.

Changes in Analyst Recommendations: Exagen Inc.

1beaa9b67368bcc9c687.MwTgibQLwlDRSDwF0BJXCzLyW_r7WZ-3ZJTFxc2-ScE.fEKp_vVNqWmiF3lEoSUGZHqDIbXINaraVsCSrpXmIqdwVNfZ0UOPHIIJdQ~2aca3b012c1b78f65b849631de50eb42
08-05 B. Riley Adjusts Price Target on Exagen to $12 From $8, Maintains Buy Rating MT
06-25 Roth Capital Initiates Exagen at Buy With $8 Price Target MT
01-30 B. Riley Cuts Price Target on Exagen to $8 From $18, Keeps Buy Rating MT
11-05 B. Riley Adjusts Exagen Price Target to $18 From $15, Maintains Buy Rating MT
11-04 Exagen Q3 revenue beats analyst expectations RE
25-09-11 B. Riley Initiates Exagen at Buy With $15 Price Target MT
25-07-30 Exagen Shares Rise After KeyBanc Upgrade MT
25-07-30 KeyBanc Upgrades Exagen to Overweight From Sector Weight, Sets $12 Price Target MT
24-05-14 Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating MT
23-03-22 BTIG Adjusts Price Target on Exagen to $5 From $6, Maintains Buy Rating MT
22-11-17 BTIG Adjusts Exagen's Price Target to $7 From $10, Keeps Buy Rating MT
22-11-15 Canaccord Genuity Cuts Price Target on Exagen to $7 From $8, Affirms Buy Rating MT
22-08-05 KeyBanc Downgrades Exagen to Sector Weight From Overweight, Citing 'Uncertain Test Pricing Process' MT
22-05-13 KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating MT
22-03-25 KeyBanc Adjusts Exagen's Price Target to $20 From $30, Reiterates Overweight Rating MT
22-03-23 Cowen Adjusts Exagen's Price Target to $16 from $26, Reiterates Outperform Rating MT
21-11-11 KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating MT
21-08-10 Exagen : BTIG Adjusts Exagen's Price Target to $20 From $23, Reiterates Buy Rating MT
21-04-15 Exagen : Canaccord Genuity Initiates Exagen at Buy Rating With $25 Price Target MT
20-11-10 Exagen : KeyBanc Initiates Exagen at Overweight with $32 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+33.23%
+25.03%
+0.38%
+2.66%
+23.48%
+6.98%
+8.55%
+7.17%
+19.97%
+15.39%
Average +14.28%
Weighted average by Cap. +12.22%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.720USD
Average target price
10.29USD
Spread / Average Target
+33.23%
High Price Target
12.00USD
Spread / Highest target
+55.44%
Low Price Target
9.000USD
Spread / Lowest Target
+16.58%

Analyst Consensus Detail

Analyst consensus - Exagen Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Exagen Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Exagen Inc.
  1. Stock Market
  2. Stocks
  3. XGN Stock
  4. Consensus Exagen Inc.